Cost-effectiveness and value of information analyses of Bruton’s tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United States-Reference-Cited by-同舟云学术

Cost-effectiveness and value of information analyses of Bruton’s tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United States

Published:2022-04 Issue:4 Volume:28 Page:390-400
ISSN:2376-0540
Container-title:Journal of Managed Care & Specialty Pharmacy
language:en
Short-container-title:JMCP

Author:

Alrawashdh Neda¹²,McBride Ali³,Slack Marion³,Persky Daniel⁴⁵,Andritsos Leslie⁶,Abraham Ivo¹²³⁵⁷

Affiliation:

1. Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ.

2. Department of Clinical Translational Sciences, College of Medicine, University of Arizona, Tucson, AZ.

3. Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ.

4. Banner University Medical Center, Tucson, AZ.

5. University of Arizona Cancer Center, Tucson, AZ.

6. University of New Mexico Comprehensive Cancer Center, Albuquerque, NM.

7. Matrix45, Tucson, AZ.

Publisher

Academy of Managed Care Pharmacy

Subject

Health Policy,Pharmaceutical Science,Pharmacy

Reference37 articles.

1. Mantle Cell Lymphoma: A Clinically Heterogeneous Disease in Need of Tailored Approaches

2. Cancer Statistics, 2021

3. A Systematic Review of Treatments of Relapsed/Refractory Mantle Cell Lymphoma

4. Current Approaches to Mantle Cell Lymphoma: Diagnosis, Prognosis, and Therapies

5. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review;Blood and Lymphatic Cancer: Targets and Therapy;2023-11

2. Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies;The Oncologist;2023-02-01